Kolon Life Science acquire approval of tumor killing virus therapy
Kolon Life Science(CEO Woo-Seok Lee) announced on the 15th that the company acquired a patent of the poxvirus promoter,’ the company’s next pipeline that increases efficacy of the oncolytic virus treatment(also known as KLS-3020) after Invossa.
According to the company, KLS-3020, a tumor killing...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
